Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cayuela Lucía, Achaval Victoria, Flox-Benítez Gema, Librero Julián, Cayuela Aurelio
Аннотация
BACKGROUND: Male breast cancer (MBC) is rare and increasing globally, with limited data on trends in Spain. The study examines MBC trends, incidence, and mortality over a 25 year period (1999-2023) to guide public health strategies.
METHODS: An ecological trend study was conducted using national mortality data from the Spanish National Statistics Institute and modeled incidence estimates from the Global Burden of Disease Study 2023. Age-standardized incidence and mortality rates (ASIR and ASMR) per 100,000 men were calculated using the European Standard Population 2013. Joinpoint regression identified temporal inflection points. Age-Period-Cohort (APC) modeling quantified age, period, and cohort effects for men aged 30-84 years.
RESULTS: The study recorded 7594 MBC cases and 1,931 deaths. ASMR declined from 0.65 to 0.39 per 100,000 (AAPC - 1.8%), with significant declines from 1999-2006 (APC - 5.1%) and 2013-2023 (APC - 3.6%). ASIR remained largely stable (AAPC 0.1%), increasing slightly from 1999-2006 (APC + 1.7%) and declining thereafter (APC - 0.5%). The Mortality-to-Incidence Ratio decreased from 0.41 to 0.26. APC analysis demonstrated significant net declines in mortality (- 1.33%/year) and incidence (- 0.83%/year), primarily driven by period effects and lower risk among later birth cohorts. Mortality reductions were most pronounced among men aged 55-64 years.
CONCLUSION: MBC mortality in Spain has declined steadily, reflecting improvements in clinical management, while stable incidence indicates minimal change in disease occurrence. Continued focus on early detection, male-specific awareness, and adherence to guideline-based therapy is essential to further reduce the MBC burden.
METHODS: An ecological trend study was conducted using national mortality data from the Spanish National Statistics Institute and modeled incidence estimates from the Global Burden of Disease Study 2023. Age-standardized incidence and mortality rates (ASIR and ASMR) per 100,000 men were calculated using the European Standard Population 2013. Joinpoint regression identified temporal inflection points. Age-Period-Cohort (APC) modeling quantified age, period, and cohort effects for men aged 30-84 years.
RESULTS: The study recorded 7594 MBC cases and 1,931 deaths. ASMR declined from 0.65 to 0.39 per 100,000 (AAPC - 1.8%), with significant declines from 1999-2006 (APC - 5.1%) and 2013-2023 (APC - 3.6%). ASIR remained largely stable (AAPC 0.1%), increasing slightly from 1999-2006 (APC + 1.7%) and declining thereafter (APC - 0.5%). The Mortality-to-Incidence Ratio decreased from 0.41 to 0.26. APC analysis demonstrated significant net declines in mortality (- 1.33%/year) and incidence (- 0.83%/year), primarily driven by period effects and lower risk among later birth cohorts. Mortality reductions were most pronounced among men aged 55-64 years.
CONCLUSION: MBC mortality in Spain has declined steadily, reflecting improvements in clinical management, while stable incidence indicates minimal change in disease occurrence. Continued focus on early detection, male-specific awareness, and adherence to guideline-based therapy is essential to further reduce the MBC burden.